963 Shares in Insulet Corporation (NASDAQ:PODD) Purchased by Advyzon Investment Management LLC

Key Points

• Advyzon Investment Management LLC has acquired a new position in Insulet Corporation, purchasing 963 shares valued at approximately $253,000 during the first quarter.
• During the same period, several large investors significantly increased their holdings in Insulet, with Allspring Global Investments increasing its stake by 55.5% and Farther Finance Advisors by 85.1%.
• Analysts have a positive outlook on Insulet, with 15 buy ratings and a current consensus price target of $321.00, highlighting strong anticipated growth for the company.

Advyzon Investment Management LLC bought a new position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 963 shares of the medical instruments supplier's stock, valued at approximately $253,000.

Several other large investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its holdings in Insulet by 55.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock valued at $1,376,000 after buying an additional 1,867 shares during the last quarter. Farther Finance Advisors LLC lifted its position in shares of Insulet by 85.1% in the first quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock valued at $236,000 after acquiring an additional 412 shares in the last quarter. QRG Capital Management Inc. boosted its stake in shares of Insulet by 75.6% during the first quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier's stock valued at $533,000 after acquiring an additional 874 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Insulet by 225.4% during the first quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock valued at $408,000 after acquiring an additional 1,075 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its position in Insulet by 2.6% during the 1st quarter. State of Alaska Department of Revenue now owns 8,212 shares of the medical instruments supplier's stock worth $2,156,000 after purchasing an additional 210 shares in the last quarter.

Insulet Stock Performance

PODD stock traded up $3.55 during trading on Friday, hitting $307.10. 1,099,682 shares of the company's stock traded hands, compared to its average volume of 619,315. The stock has a market capitalization of $21.61 billion, a price-to-earnings ratio of 93.34, a price-to-earnings-growth ratio of 2.69 and a beta of 1.35. Insulet Corporation has a 52 week low of $173.00 and a 52 week high of $329.33. The stock has a fifty day moving average price of $299.12 and a two-hundred day moving average price of $283.00. The company has a quick ratio of 3.63, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. During the same quarter in the prior year, the business earned $0.55 earnings per share. Insulet's quarterly revenue was up 32.9% on a year-over-year basis. As a group, equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of recent research reports. Wolfe Research upgraded shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price on the stock in a report on Tuesday, May 13th. Raymond James Financial reissued an "outperform" rating and set a $360.00 price objective (up previously from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Morgan Stanley restated an "overweight" rating on shares of Insulet in a research report on Thursday. Canaccord Genuity Group boosted their price target on Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a report on Friday. Finally, Truist Financial began coverage on Insulet in a report on Monday, June 16th. They set a "buy" rating and a $365.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $324.72.

Insider Activity

In related news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the sale, the senior vice president directly owned 23,180 shares in the company, valued at $7,382,134.60. This trade represents a 18.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.39% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.